CRC Research Update — October 30, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 943 issues
New predictive model identifies mismatch repair deficiency in resource-limited settings
Skip to content
The CRC Digest
New predictive model identifies mismatch repair deficiency in resource-limited settings
Cross-sectional analysis of 185 Sri Lankan patients found 12.4% were mismatch repair deficient; multivariable analysis identified age under 60, right-sided tumors, family history, and specific histologic features as significant predictors. (BMC Cancer)
This
Obesity reshapes gut microbiota and drives early-onset CRC through dysbiosis and inflammation
Skip to content
The CRC Digest
Obesity reshapes gut microbiota and drives early-onset CRC through dysbiosis and inflammation
Narrative review explores how diet-induced adiposity depletes protective bacteria, enriches genotoxic pathobionts, and promotes systemic inflammation that creates a fertile niche for early-onset carcinogenesis. (In Vivo)
This content is informational only and
Dual-gene stool DNA test achieves 82.9% sensitivity for colorectal cancer detection
Skip to content
The CRC Digest
▪ SCREENING
Dual-gene stool DNA test achieves 82.9% sensitivity for colorectal cancer detection
Cross-sectional study of 274 participants found combined SDC2 and ADHFE1 methylation analysis in stool samples detected colorectal cancer with 82.9% sensitivity and an AUC of 0.865, though discrimination of
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Skip to content
The CRC Digest
◇ RESEARCH
PIK3C3 inhibition enhances 5-FU sensitivity in KRAS-mutant cells, opposite effect in KRAS-wild-type
Laboratory study found PIK3C3 knockdown increased 5-fluorouracil resistance in KRAS-wild-type cells but enhanced sensitivity in KRAS-mutant cells, potentially through thymidylate synthase regulation. (Cancer Medicine)
This content is informational only and does
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Meta-analysis of 18 randomized trials (11,931 participants) found pooled median overall survival of 22.3 months for BRAF-directed regimens versus 10.1 months for EGFR-directed therapy in first-line treatment. (Journal of Gastrointestinal
Single-cell atlas reveals early-onset colorectal cancer has more stroma, less tumor epithelium
Skip to content
The CRC Digest
◇ RESEARCH
Single-cell atlas reveals early-onset colorectal cancer has more stroma, less tumor epithelium
Analysis of 189 tumors spanning eight decades found that microsatellite-stable tumors from younger patients had increased stromal and decreased epithelial proportions, with epithelial cells showing higher expression of long noncoding RNAs
CRC Research Update — October 29, 2026
Today's colorectal cancer research highlights
Pharmacokinetic method developed for pan-RAS inhibitor
Skip to content
The CRC Digest
▸ TREATMENT
Pharmacokinetic method developed for pan-RAS inhibitor
Researchers validated a mass spectrometry assay to measure daraxonrasib, an oral pan-RAS inhibitor in clinical evaluation for colorectal cancer, in canine plasma and whole blood, supporting pharmacokinetic characterization of the investigational drug. (Biomed Chromatogr)
This content is
Review outlines strategies for identifying Lynch syndrome
Skip to content
The CRC Digest
◇ RESEARCH
Review outlines strategies for identifying Lynch syndrome
A review in Familial Cancer summarizes established and emerging approaches to Lynch syndrome detection in patients with colorectal neoplasia, noting that tumor-based mismatch repair testing remains cost-efficient but limited by incomplete implementation, while direct germline testing